Takeda would be one of many. By value of other drugs we can make some conclusions. This one is in early development but they still paid 4 billion cash plus they add 2 billion on sale mile stones. Big deals do happen.
Now looking at Remestemcel, we have mode of action for GVHD and we have results. They are already accross other indications including IBD. We have the potancy assay. Given FDA approval our product is worth something well north of above.
Is 4 billion cash plus 20 % of sales over the top?
MSB Price at posting:
92.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)